Anixa Biosciences Inc ANIX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ANIX is a good fit for your portfolio.
News
-
Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy
-
Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology
-
Anixa Biosciences Announces $5 Million Share Repurchase Program
-
Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial
-
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
-
Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
-
Sidoti Events, LLC's Virtual May Micro-Cap Conference
-
Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja
Trading Information
- Previous Close Price
- $2.89
- Day Range
- $2.87–3.12
- 52-Week Range
- $2.15–5.13
- Bid/Ask
- $3.01 / $3.09
- Market Cap
- $97.62 Mil
- Volume/Avg
- 141,747 / 104,582
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 451.85
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.anixa.com
Comparables
Valuation
|
Metric
|
ANIX
|
ITOS
|
ADPT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.94 | 1.14 | 2.42 |
Price/Sales | 451.85 | — | 3.75 |
Price/Cash Flow | — | — | — |
Price/Earnings
ANIX
ITOS
ADPT
Financial Strength
|
Metric
|
ANIX
|
ITOS
|
ADPT
|
|---|---|---|---|
Quick Ratio | 13.95 | 12.80 | 4.23 |
Current Ratio | 14.40 | 13.51 | 4.51 |
Interest Coverage | — | — | −16.48 |
Quick Ratio
ANIX
ITOS
ADPT
Profitability
|
Metric
|
ANIX
|
ITOS
|
ADPT
|
|---|---|---|---|
Return on Assets (Normalized) | −27.36% | −16.56% | −17.89% |
Return on Equity (Normalized) | −28.36% | −18.86% | −36.02% |
Return on Invested Capital (Normalized) | −34.38% | −22.78% | −28.77% |
Return on Assets
ANIX
ITOS
ADPT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Xdnnlrsvjd | Skp | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tlypjtmsj | Fmtjx | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Qptkhdfr | Gvwyfg | $118.7 Bil | |||
| Moderna Inc
MRNA
| Lfwdkbyy | Sdnz | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vltdtxf | Cgtmdx | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Kxbgtwfft | Vrk | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Gsqnhtsnk | Tgb | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gcwyyxkg | Mncczcr | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Bvlhkxmz | Mlnbv | $15.0 Bil | |||
| Incyte Corp
INCY
| Cbzkflg | Kngxwpt | $13.5 Bil |